<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Gastroenterology - Latest articles</title>
		<link>http://www.biomedcentral.com/bmcgastroenterol/</link>
		<description>The latest articles from BMC Gastroenterology (ISSN 1471-230X) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/14"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/13"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/12"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/11"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/10"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/9"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/8"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/7"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/6"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/8/5"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/14">
            
            <title>Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: A prospective study</title>
			<description>Background:
Cell death mode has been studied in cancer, autoimmune, and neurodegenerative diseases. In this study, apoptosis and necrosis are investigated for the first time in patients with chronic calculous cholecystitis.
Methods:
Thirty five (35) patients (27 women and 8 men, aged 55.65+/-13.48 years) with symptomatic chronic calculous cholecystitis underwent laparoscopic cholecystectomy. The early specific apoptotic tendency (caspase-cleaved cytokeratin 18) was studied in these patients with M30 Apoptosense ELISA and the total cytokerarin 18 (both derived from apoptosis and necrosis) with M65 ELISA. The ratio M30/M65 (caspase-cleaved to total cytokeratin 18) was also computed. According to the histopathological examination, the patients were divided in two groups: group A included patients with chronic inactive cholecystitis (n=10), and group B those with chronic active cholecystitis (n=25).
Results:
The concentrations of caspase-cleaved cytokerarin 18 (CK18), and especially those of total CK18, were higher in bile samples than in serum samples. In group B, there were significant differences between serum and bile samples regarding both caspase-cleaved CK18 and total CK18. Cells staining positive for caspase-cleaved CK18 were present in the epithelial cells of the mucosa of the gallbladder.
Conclusions:
CK18 is expressed in the gallbladder epithelial cells. The concentrations of both caspase-cleaved CK18 and total CK18 were higher in bile samples than in serum samples. The levels of total CK18, as well as caspase-cleaved CK18, do not seem to differ between active and inactive chronic cholecystitis.</description>
			<link>http://www.biomedcentral.com/1471-230X/8/14</link>
			
			 	<dc:creator>Constantinos Simopoulos, Alexandra K Tsaroucha, Byron Asimakopoulos, Alexandra Giatromanolaki, Paschalis Gavriilidis, Alexandros Polychronidis and Anastasios Karayiannakis</dc:creator>
			
			<dc:source>BMC Gastroenterology 2008, 8:14</dc:source>
			<dc:date>2008-05-06</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-14</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>14</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-06</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/13">
            
            <title>Prevalence and determinants of biochemical dysfunction of the liver in Atayal aboriginal community of Taiwan: Is betel nut chewing a risk factor?</title>
			<description>Background:
We address the independent and interactive roles of habitual betel quid chewing and other known risk factors for biochemical dysfunction and cirrhosis of the liver. 
Methods:
To determine the prevalence rates and risk factors associated with biochemical dysfunction of the liver, a total of 3,010 adult residents in an Atayal Aboriginal community were invited to participate in the study. Abdominal ultrasonography was used to diagnose liver cirrhosis. 
Results:
There were 2,063 Atayal Aboriginal and 947 non-Aboriginal in this study. The result showed overall prevalence rates for hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) were 21.2 % and 2.9 %, respectively. There were 16.5 %, 15.1 % and 22.4 % subjects with abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma glutamyl transpeptidase (GGT), accordingly. Multiple logistic regression analysis showed that combined infections with HBV and HCV presented with the highest risks with OR (odds ratio) and 95% CI (confidence interval) of 4.2 (1.2-17.4) and 3.8 (1.0-14.1), respectively for elevation of ALT and AST; followed by alcohol (1.7 and 3.1), male gender (1.7 and 1.6), betel quid (1.5 and 1.3), smoking (1.4 and 1.8), and aboriginal (1.4 and 1.3). There is effect-measure modification between viral infection and betel quid chewing for increased severity of abnormal ALT elevation. Among 1,382 subjects consenting to abdominal ultrasonography, 41(3.0%) were found to have liver cirrhosis with the same factors associated with higher risks.  Conclusions: In addition to infections with viral hepatitis B and/or C, we found Atayal Aboriginal, males, current smokers, drinkers and betel quid chewers were independently associated with biochemical dysfunction and probably cirrhosis of the liver. Further study is needed to corroborate the above hypothesis. </description>
			<link>http://www.biomedcentral.com/1471-230X/8/13</link>
			
			 	<dc:creator>Ching-Feng Lin, Tun-Jen Shiau, Ying-Chin Ko, Ping-Ho Chen and Jung-Der Wang</dc:creator>
			
			<dc:source>BMC Gastroenterology 2008, 8:13</dc:source>
			<dc:date>2008-04-27</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-13</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/12">
            
            <title>Rebleeding rate after interventional therapy directed by capsule endoscopy in patients with obscure gastrointestinal bleeding</title>
			<description>Background:
The precise role of capsule endoscopy in the diagnostic algorithm of obscure gastrointestinal bleeding has yet to be determined. Despite the higher diagnostic yield of capsule endoscopy, the actual impact on clinical outcome remains poorly defined. The aim of this study was to evaluate the follow-up results of patients with obscure gastrointestinal bleeding to determine which management strategies after capsule endoscopy reduced rebleeding.
Methods:
All patients in whom the cause of obscure gastrointestinal bleeding was investigated between May 2004 and March 2007 were studied retrospectively. We evaluated the clinical outcome of patients with obscure gastrointestinal bleeding after capsule endoscopy using the rebleeding rate as the primary outcome. 
Results:
Seventy-seven patients with obscure gastrointestinal bleeding underwent capsule endoscopy. Capsule endoscopy identified clinically significant findings that were thought to be the sources of obscure gastrointestinal bleeding in 58.4% of the patients. The overall rebleeding rate was 36.4%. The rebleeding rate was significantly higher among patients with insignificant findings than among those with significant findings (p = 0.036). Among the patients in whom capsule endoscopy produced significant findings, the rebleeding rate of the patients who underwent therapeutic interventions was significantly lower than that in those who did not undergo intervention (9.5% vs 40.0%, p = 0.046).
Conclusions:
Follow-up and further aggressive interventions are necessary for patients with obscure gastrointestinal bleeding and significant capsule endoscopy findings to reduce the chance of rebleeding.</description>
			<link>http://www.biomedcentral.com/1471-230X/8/12</link>
			
			 	<dc:creator>Hiroki Endo, Nobuyuki Matsuhashi, Masahiko Inamori, Keiko Akimoto, Tomohiko Ohya, Tatsuro Yanagawa, Masako Asayama, Kantaro Hisatomi, Takuma Teratani, Koji Fujita, Masato Yoneda and Atsushi Nakajima</dc:creator>
			
			<dc:source>BMC Gastroenterology 2008, 8:12</dc:source>
			<dc:date>2008-04-23</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-12</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>12</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-23</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/11">
            
            <title>Effects of pectin liquid on gastroesophageal reflux disease in children with cerebral palsy</title>
			<description>Background:
The use of thickeners is a standard therapy for decreasing episodes of regurgitation or vomiting in infants. However, it remains to be investigated whether thickener is effective for vomiting and/or chronic respiratory symptoms in children with cerebral palsy.
Methods:
We enrolled 18 neurologically impaired children caused by cerebral palsy, with gastroesophageal reflux disease. In the first part of this study (pH monitoring), subjects were randomly allocated to two groups: fed with a high-pectin diet [enteral formula: pectin liquid = 2:1 (v/v)], or a low-pectin diet [enteral formula: pectin liquid = 3:1 (v/v)]. Two-channel esophageal pH monitoring was performed over 48 h. In the second part (clinical trial), subjects were fed a high- or low-pectin diet and non-pectin diet for 4 weeks in a crossover manner. Nurses recorded the feeding volume, number of episodes of vomiting, volume of gastric residue, episodes of cough and wheeze, frequency of using oxygen for dyspnea, and the day when the child could return to school. Cough and wheeze were recorded as a cough-score.
Results:
The median value for the % time pH &lt; 4 at the lower and upper esophagus was significantly decreased with a high-pectin diet [9.2% (6.2&#8211;22.6) vs. 5.0% (3.1&#8211;13.1); P &lt; 0.01, 3.8% (2.9&#8211;11.2) vs. 1.6% (0.9&#8211;8.9); P &lt; 0.01 (interquartile range), non-pectin and high-pectin, respectively]. The number of reflux episodes per day and duration of longest reflux were decreased significantly with a high-pectin, but not with a low-pectin diet. The median number of episodes of vomiting decreased significantly with a high-pectin diet [2.5/week (1.0&#8211;5.0) vs. 1.0 (1.0&#8211;1.5), P &lt; 0.05]. The median cough-score was significantly decreased by both concentrations of pectin [8.5/week (1.0&#8211;11.5) vs. 2.0/week (0.0&#8211;3.0), fed with a high-pectin diet; 7.0/week (1.0&#8211;14.5) vs. 1.0/w (0.0&#8211;5.0), fed with a low-pectin diet, P &lt; 0.05].
Conclusion:
Pectin liquid partially decreased gastroesophageal reflux as measured by eshophageal pH monitoring, and might improve vomiting and respiratory symptoms in children with cerebral palsy.Trial registrationISRCTN19787793</description>
			<link>http://www.biomedcentral.com/1471-230X/8/11</link>
			
			 	<dc:creator>Reiko Miyazawa, Takeshi Tomomasa, Hiroaki Kaneko, Hirokazu Arakawa, Nobuzo Shimizu and Akihiro Morikawa</dc:creator>
			
			<dc:source>BMC Gastroenterology 2008, 8:11</dc:source>
			<dc:date>2008-04-16</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-11</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>11</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-16</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/10">
            
            <title>Inverse association between gastroesophageal reflux and blood pressure: Results of a large community based study</title>
			<description>Background:
In a cross-sectional community based study, as part of a randomised controlled trial of eradication of Helicobacter pylori infection, the association between blood pressure and symptoms of gastro-oesophageal reflux was examined.
Methods:
Linear regression was used to examine the association between systolic and diastolic blood pressure and the frequency of heartburn and acid regurgitation in 4,902 of 10,537 participants aged 20&#8211;59 years.
Results:
In multivariable analyses, adjusted mean systolic blood pressure was 4.2 (95% confidence interval 1.5 to 7.0) mm Hg lower in participants with daily acid regurgitation compared to those with less frequent symptoms. Similarly, for diastolic blood pressure, a reduction of 2.1 (0.0 to 4.3) mm Hg wasobserved.
Conclusion:
People who experience daily symptoms of gastro-oesophageal reflux have lower blood pressure than people with less frequent or no symptoms. It is possible that factors influencing nitric oxide concentrations both at the lower oesophageal sphincter and within the vasculature may be involved. This hypothesis requires confirmation.Trials registration numberISRCTN44816925</description>
			<link>http://www.biomedcentral.com/1471-230X/8/10</link>
			
			 	<dc:creator>Liam J Murray, Peter McCarron, Roger B McCorry, Lesley A Anderson, Athene J Lane, Brian T Johnston, George Davey Smith and Richard F Harvey</dc:creator>
			
			<dc:source>BMC Gastroenterology 2008, 8:10</dc:source>
			<dc:date>2008-04-15</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-10</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>10</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/9">
            
            <title>Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa</title>
			<description>Background:
Human gastrointestinal mucosa regenerates vigorously throughout life, but the factors controlling cell fate in mature mucosa are poorly understood. GATA transcription factors direct cell proliferation and differentiation in many organs, and are implicated in tumorigenesis. GATA-4 and GATA-6 are considered crucial for the formation of murine gastrointestinal mucosa, but their role in human gastrointestinal tract remains unexplored. We studied in detail the expression patterns of these two GATA factors and a GATA-6 down-stream target, Indian hedgehog (Ihh), in normal human gastrointestinal mucosa. Since these factors are considered important for proliferation and differentiation, we also explored the possible alterations in their expression in gastrointestinal neoplasias. The expression of the carcinogenesis-related protein Indian hedgehog was also investigated in comparison to GATA factors.
Methods:
Samples of normal and neoplastic gastrointestinal tract from children and adults were subjected to RNA in situ hybridization with 33P labelled probes and immunohistochemistry, using an avidin-biotin immunoperoxidase system. The pathological tissues examined included samples of chronic and atrophic gastritis as well as adenomas and adenocarcinomas of the colon and rectum.
Results:
GATA-4 was abundant in the differentiated epithelial cells of the proximal parts of the gastrointestinal tract but was absent from the distal parts. In contrast, GATA-6 was expressed throughout the gastrointestinal epithelium, and in the distal gut its expression was most intense at the bottom of the crypts, i.e. cells with proliferative capacity. Both factors were also present in Barrett's esophagus and metaplasia of the stomach. GATA-6 expression was reduced in colon carcinoma. Ihh expression overlapped with that of GATA-6 especially in benign gastrointestinal neoplasias.
Conclusion:
The results suggest differential but overlapping functions for GATA-4 and GATA-6 in the normal gastrointestinal mucosa. Furthermore, GATA-4, GATA-6 and Ihh expression is altered in premalignant dysplastic lesions and reduced in overt cancer.</description>
			<link>http://www.biomedcentral.com/1471-230X/8/9</link>
			
			 	<dc:creator>Hanna Haveri, Mia Westerholm-Ormio, Katri Lindfors, Markku M&#228;ki, Erkki Savilahti, Leif C Andersson and Markku Heikinheimo</dc:creator>
			
			<dc:source>BMC Gastroenterology 2008, 8:9</dc:source>
			<dc:date>2008-04-11</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-9</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>9</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/8">
            
            <title>A self administered reliable questionnaire to assess lower bowel symptoms</title>
			<description>Background:
Bowel symptoms are considered indicators of the presence of colorectal cancer and other bowel diseases. Self administered questionnaires that elicit information about lower bowel symptoms have not been assessed for reliability, although this has been done for upper bowel symptoms. Our aim was to develop a self administered questionnaire for eliciting the presence, nature and severity of lower bowel symptoms potentially related to colorectal cancer, and assess its reliability.
Methods:
Immediately before consulting a gastroenterologist or colorectal surgeon, 263 patients likely to have a colonoscopy completed the questionnaire. Reliability was assessed in two ways: by assessing agreement between patient responses and (a) responses given by the doctor at the consultation; and (b) responses given by patients two weeks later.
Results:
There was more than 75% agreement for 78% of the questions for the patient-doctor comparison and for 92% of the questions for the patient-patient comparison. Agreement for the length of time a symptom was present, its severity, duration, frequency of occurrence and whether or not medical consultation had been sought, all had agreement of greater than 70%. Over all questions, the chance corrected agreement for the patient-doctor comparison had a median kappa of 65% (which represents substantial agreement), interquartile range 57&#8211;72%. The patient-patient comparison also showed substantial agreement with a median kappa of 75%, interquartile range 68&#8211;81%.
Conclusion:
This self administered questionnaire about lower bowel symptoms is a useful way of eliciting details of bowel symptoms. It is a reliable instrument that is acceptable to patients and easily completed. Its use could guide the clinical consultation, allowing a more efficient, comprehensive and useful interaction, ensuring that all symptoms are assessed. It will also be a useful tool in research studies on bowel symptoms and their predictive value for colorectal cancer and other diseases. Studies assessing whether bowel symptoms predict the presence of colorectal cancer should provide estimates of the reliability of the symptom elicitation.</description>
			<link>http://www.biomedcentral.com/1471-230X/8/8</link>
			
			 	<dc:creator>Barbara-Ann Adelstein, Les Irwig, Petra Macaskill, Peter H Katelaris, David B Jones and Les Bokey</dc:creator>
			
			<dc:source>BMC Gastroenterology 2008, 8:8</dc:source>
			<dc:date>2008-03-01</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-8</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>8</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-03-01</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/7">
            
            <title>Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma</title>
			<description>Background:
Studies on gastrointestinal symptoms, dysfunctions, and neurological disorders in systemic scleroderma are lacking so far.
Methods:
Thirty-eight scleroderma patients (34 limited, 4 diffuse), 60 healthy controls and 68 dyspeptic controls were scored for upper and lower gastrointestinal symptoms (dyspepsia, bowel habits), gastric and gallbladder emptying to liquid meal (functional ultrasonography) and small bowel transit (H2-breath test). Autonomic nerve function was assessed by cardiovascular tests.
Results:
The score for dyspepsia (mainly gastric fullness) was greater in scleroderma patients than healthy controls, but lower than dyspeptic controls who had multiple symptoms, instead. Scleroderma patients with dyspepsia had a longer disease duration. Fasting antral area and postprandial antral dilatation were smaller in scleroderma patients than dyspeptic and healthy controls. Gastric emptying was delayed in both scleroderma patients (particularly in those with abnormal dyspeptic score) and dyspeptic controls, who also showed a larger residual area. Despite gallbladder fasting and postprandial volumes were comparable across the three groups, gallbladder refilling appeared delayed in dyspeptic controls and mainly dependent on delayed gastric emptying in scleroderma. Small intestinal transit was also delayed in 74% of scleroderma and 66% of dyspeptic controls. Bowel habits were similar among the three groups. Autonomic neuropathy was not associated with dyspepsia, gastric and gallbladder motility and small intestinal transit.
Conclusion:
In scleroderma patients dyspepsia (mainly gastric fullness), restricted distension of the gastric antrum and diffuse gastrointestinal dysmotility are frequent features. These defects are independent from the occurrence of autonomic neuropathy.</description>
			<link>http://www.biomedcentral.com/1471-230X/8/7</link>
			
			 	<dc:creator>Agostino Di Ciaula, Michele Covelli, Massimo Berardino, David QH Wang, Giovanni Lapadula, Giuseppe Palasciano and Piero Portincasa</dc:creator>
			
			<dc:source>BMC Gastroenterology 2008, 8:7</dc:source>
			<dc:date>2008-02-27</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-7</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/6">
            
            <title>Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis</title>
			<description>Background:
Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography and benefit of pharmacological treatment is unclear. Although prophylactic use of corticosteroid for reduction of pancreatic injury after ERCP has been evaluated, discrepancy about beneficial effect of corticosteroid on pancreatic injury still exists. The aim of current study is to evaluate effectiveness and safety of corticosteroid in prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP).
Methods:
We employed the method recommended by the Cochrane Collaboration to perform a meta-analysis of seven randomized controlled trials (RCTs) of corticosteroid in prevention of post-ERCP pancreatitis (PEP) around the world.
Results:
Most of the seven RCTs were of high quality. When the RCTs were analyzed, odds ratios (OR) for corticosteroid were 1.13 [95% CI (0.89~1.44), p = 0.32] for PEP, 1.61 [95% CI (0.74~3.52), p = 0.23] for severe PEP, 0.92 [95% CI (0.57~1.48), p = 0.73] for post-ERCP hyperamylasemia respectively. The results indicated that there were no beneficial effects of corticosteroid on acute pancreatitis and hyperamylasemia. No evidence of publication bias was found.
Conclusion:
Corticosteroids cannot prevent pancreatic injury after ERCP. Therefore, their use in the prophylaxis of PEP is not recommended.</description>
			<link>http://www.biomedcentral.com/1471-230X/8/6</link>
			
			 	<dc:creator>Minghua Zheng, Jianling Bai, Bosi Yuan, Feng Lin, Jie You, Mingqin Lu, Yuewen Gong and Yongping Chen</dc:creator>
			
			<dc:source>BMC Gastroenterology 2008, 8:6</dc:source>
			<dc:date>2008-02-14</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-6</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>6</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-14</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-230X/8/5">
            
            <title>Epidemiology of constipation in Europe and Oceania: a systematic review</title>
			<description>Background:
We aimed to review the literature regarding the epidemiology of constipation in Europe and Oceania and the associated prevalence/risk factors.
Methods:
Two reviewers performed PubMed searches and a hand search of references. A study was considered eligible for inclusion if it reported data about the prevalence of constipation in any population, free of other gastrointestinal disorders, in Europe and Oceania. Studies were evaluated for quality. Data regarding the setting, type of study, definition of constipation, study population, prevalence of constipation, factors associated with increased odds for constipation, and the female to male ratio, were collected.
Results:
The 21 reviewed studies depict prevalence rates in 34 different population groups ranging widely from a low 0.7% to a high 81%. In the general population of Europe the mean value of the reported constipation rates is 17,1 % and the median value 16.6%. Among the studies conducted in Oceania, the mean value of constipation prevalence was 15.3%. Female gender, age and socioeconomic and educational class seem to have major effect on constipation prevalence. A number of various other risk factors are, less clearly, associated with constipation.
Conclusion:
This systematic review depicts the high prevalence and related risk factors of a disorder that decreases the health-related quality of life and has major economic consequences.</description>
			<link>http://www.biomedcentral.com/1471-230X/8/5</link>
			
			 	<dc:creator>George Peppas, Vangelis G Alexiou, Eleni Mourtzoukou and Matthew E Falagas</dc:creator>
			
			<dc:source>BMC Gastroenterology 2008, 8:5</dc:source>
			<dc:date>2008-02-12</dc:date>
			<dc:identifier>doi:10.1186/1471-230X-8-5</dc:identifier>
			
			
							
					<prism:publicationName>BMC Gastroenterology</prism:publicationName>
					
			
							
					<prism:issn>1471-230X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
